Site Editor

Leo I. Gordon, MD, FACP


Lisocabtagene Maraleucel Approved by FDA in Second-Line Treatment of LBCL

By: JNCCN 360 Staff
Posted: Tuesday, June 28, 2022

On June 24, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (Breyanzi) for adults with large B-cell lymphoma (LBCL) who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age. The CD19-directed chimeric antigen receptor (CAR) T-cell therapy is not indicated for the treatment of patients with primary central nervous system lymphoma.

Efficacy of lisocabtagene maraleucel was evaluated in TRANSFORM, a randomized, open-label, multicenter trial in adults with primary refractory LBCL or relapse within 12 months of achieving complete response to first-line therapy. Patients had not yet received treatment of relapsed or refractory lymphoma and were potential candidates for autologous HSCT. A total of 184 patients were randomly assigned 1:1 to receive a single infusion of lisocabtagene maraleucel following fludarabine and cyclophosphamide lymphodepleting chemotherapy or second-line standard therapy, consisting of three cycles of chemoimmunotherapy followed by high-dose therapy and autologous HSCT in those who attained a complete response or a partial response.

The primary efficacy measure was event-free survival (EFS), as determined by an independent review committee. EFS was significantly longer with lisocabtagene maraleucel, with a hazard ratio (HR) of 0.34 (P < .0001). The estimated 1-year EFS was 45% with lisocabtagene maraleucel and 24% with standard therapy. The estimated median EFS was 10.1 months and 2.3 months, respectively. The independent review committee–assessed progression-free survival was also significantly longer with lisocabtagene maraleucel, with a HR of 0.41 (P = .0001).

The FDA approved lisocabtagene maraleucel with a Risk Evaluation and Mitigation Strategy because of the risk of fatal or life-threatening cytokine-release syndrome and neurologic toxicities. In studies of lisocabtagene maraleucel as second-line therapy for LBCL, cytokine-release syndrome occurred in 45% of patients (≥ grade 3, 1.3%), and neurologic toxicities occurred in 27% (grade 3, 7%).

The recommended lisocabtagene maraleucel dose for second-line therapy is 90 to 110 × 106 CAR-positive T cells, with a 1:1 ratio of CD4 and CD8 components.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.